4905S-10: S0819 NSCLC

SWOG 0819: Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Type of Study
Cancer (Oncology) - Lung
Location
Swedish Cancer Institute
Short Description

Purpose: This randomized phase III trial is studying carboplatin and paclitaxel to compare how well they work with or without bevacizumab and/or cetuximab in treating patients with stage IV or recurrent non-small cell lung cancer.

 

 

Status
Open to Enrollment
Principal Investigator
Gary Goodman, M.D.
Eligibility Notes
  • Histologically or cytologically confirmed non-small cell lung cancer, including any of the following subtypes:

     

    • Adenocarcinoma

       

       

    • Large cell carcinoma

       

       

    • Squamous cell carcinoma

       

       

    • Unspecified

       

     

  • Newly diagnosed stage IV disease OR recurrent disease after prior surgery and/or irradiation

     

     

  • Brain metastases allowed provided they have been controlled for ≥ 2 months after completion of treatment and there is no residual neurological dysfunction while off corticosteroids

     

     

  • Zubrod performance status 0-1

     

     

  • Must be willing to provide prior smoking history

     

     

  • Prior radiotherapy allowed provided patients have recovered from all associated toxicities at the time of study registration

     

     

  • No prior chemotherapy, cetuximab, gefitinib, erlotinib, or other investigational agents that target the EGFR pathway

     

     

  • No prior bevacizumab or VEGF-related agents

     

     

  • No prior chimerized or murine monoclonal antibody therapy

     

     

  • At least 28 days since prior surgery (thoracic or other major surgeries) or open biopsy and recovered

  • No concurrent major surgical procedures

More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
Phone
(206) 215-3086
Email
CancerResearch@swedish.org